Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer
NCT07398560Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Countries
- 1
- Sponsor
- Third Affiliated Hospital of Harbin Medical University
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- adebrelimab
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Third Affiliated Hospital of Harbin Medical University. Primary endpoint: Progression-Free Survival up to 24 months. Planned start Feb 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Adebrelimab Combined with Oral Etoposide
Experimental arm receiving Adebrelimab and Oral Etoposide.
03
Who it enrols
Patients with extensive-stage or locally advanced small cell lung cancer at initial diagnosis, who are elderly (>=65 years) or have poor performance status (ECOG 2-3), or have specific comorbidities. Must have measurable disease, adequate organ function, and no active autoimmune disease, severe heart disease, or active infections.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Objective Response Rate
Disease Control Rate
Overall Survival
Incidence of adverse events
Patient-Reported Outcomes
Beyond the preview
Go deeper on NCT07398560.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398560.